Increased sensitivity of myeloid leukemia cell lines: Potential of lovastatin as bone-marrow-purging agent

Acta Haematologica

Volumn 104, Issue 2-3, 2000, Pages 72-79

  Scheffold, Christian ^a   Schöttker, Björn ^b   Lefterova, Petja ^b   Csipai, Markus ^c   Glasmacher, Axel ^b   Huhn, Dieter ^c   Neubauer, Andreas ^d   Schmidt Wolf, Ingo G H ^b,e  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF BONN   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Bone marrow purging; Bone marrow transplantation; HMG CoA reductase; Myelogenous leukemia; ras

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MAFOSFAMIDE; MEVINOLIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW PURGING; BONE MARROW TRANSPLANTATION; CANCER CELL DESTRUCTION; CELL STRAIN K 562; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG SENSITIVITY; ERYTHROLEUKEMIA; HUMAN; HUMAN CELL; ONCOGENE RAS; PRIORITY JOURNAL;

BONE MARROW CELLS; BONE MARROW PURGING; BONE MARROW TRANSPLANTATION; CELL SURVIVAL; CLONE CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GROWTH INHIBITORS; HEMATOPOIETIC STEM CELLS; HUMANS; K562 CELLS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; LOVASTATIN; MONOCYTES; TRANSPLANTATION, AUTOLOGOUS;

EID: 0034517213     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000039755     Document Type: Article

References (38)

1. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide
2. Elimination of leukemia cells from human bone marrow using monoclonal antibody and complement
3. Anti-B1 monoclonal antibody and complement treatment in autologous bone marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma
4. Use of the polymerase chain reaction to monitor the effectiveness of ex vivo tumor cell purging
5. The use of monoclonal antibodies for purging autologous bone marrow in lymphoid malignancies
6. Pharmacologic purging of bone marrow with reference to autografting
7. Removal of tumor cells from bone marrow: An evaluation of the available techniques
8. Transplantation of leukemic bone marrow treated with cytotoxic antileukemic antibodies and complement
9. Elimination of leukemic cells from rat bone marrow using antibody and complement
10. Myeloid associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies
11. Neoplastic B cell targets for antibody-ricin A chain immunotoxins
12. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis
13. Autologous bone marrow transplantation in acute leukemia: In vitro treatment with myeloid cell-specific monoclonal antibodies
14. Differential inhibitory effects of lovastatin on protein isoprenylation
15. Genetic and pharmacological supression of oncogenic mutations in ras genes of yeast and humans
16. Inhibition of cell growth by lovastatin is independent of ras function
17. Properties and usefulness of the original K-562 human myelogenous leukemia cell line
18. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity
19. A combined approach for multidrug-resistant leukemia cell lines in bone marrow using a monoclonal antibody and chemotherapy
20. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and xytotoxicity assays
21. Detection of breakpoint cluster region-negative and nonclonal hematopoiesis in vitro and in vivo after transplantation of cells selected in cultures of chronic myeloid leukemia marrow
22. Successful autografting in chronic myeloid leukemia after maintenance of marrow in culture
23. Can long-term bone marrow culture eliminate leukemia cells?
24. 1)-negative hematopoiesis in patients selected by prior assessment of their marrow in vitro
25. Separating the wheat from the chaff: Selection of benign hematopoietic cells in chronic myeloid leukemia
26. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages
27. Ras C-terminal processing enzymes - New drug targets?
28. Induction of apoptosis by lovastatin through activation of caspase-3 and Dnase II in leukaemia HL-60 cells
29. Synergistic effect of 4-hydroperoxyclo-phosphamides and etoposide on a human promyelocytic leukemia cell line (HL-60) demonstrated by computer analysis
30. Efficacy of a combined treatment with ASTA-Z 7654 and VP16-213 in vitro in eradicating clonogenic tumor cells from human bone marrow
31. Preclinical studies of the combination of mafosfamide (ASTA-Z 7654) and etoposide (VP16-213) for purging leukemic autologous marrow
32. In vitro evaluation of combination drug purging for autologous bone marrow transplantation
33. Potential of phenylalanine methylester as a bone marrow purging agent
34. Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purged marrows for acute nonlymphocytic leukemia in late remission or early relapse
35. Conditions controlling the proliferation of hematopoietic stem cells in vitro
36. Today's SCID-hu mouse
37. Increased sensitivity of AML to lovastatin-induced apoptosis: A potential therapeutic approach
38. A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal marrow progenitors